Switch theme
Sign up to access all valuation multiples
Garofalo Health Care SpA operates accredited private healthcare facilities and is based in Rome. The company offers outpatient services and other range of services including surgery, emergency medicine, clinical, interventional cardiology, nutritional rehabilitation, and diagnostic centers among others.
2000
2.7K+
LTM Revenue $534M
LTM EBITDA $89.4M
$758M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Garofalo Health Care has a last 12-month revenue (LTM) of $534M and a last 12-month EBITDA of $89.4M.
In the most recent fiscal year, Garofalo Health Care achieved revenue of $525M and an EBITDA of $78.6M.
Garofalo Health Care expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Garofalo Health Care valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $534M | XXX | $525M | XXX | XXX | XXX |
| Gross Profit | $534M | XXX | $447M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 85% | XXX | XXX | XXX |
| EBITDA | $89.4M | XXX | $78.6M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 15% | XXX | XXX | XXX |
| EBIT | $52.3M | XXX | $61.6M | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $26.8M | XXX | $24.4M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $197M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Garofalo Health Care's stock price is EUR 5 (or $6).
Garofalo Health Care has current market cap of EUR 461M (or $518M), and EV of EUR 675M (or $758M).
See Garofalo Health Care trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $758M | $518M | XXX | XXX | XXX | XXX | $0.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Garofalo Health Care has market cap of $518M and EV of $758M.
Garofalo Health Care's trades at 1.4x EV/Revenue multiple, and 9.7x EV/EBITDA.
Equity research analysts estimate Garofalo Health Care's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Garofalo Health Care has a P/E ratio of 19.3x.
See valuation multiples for Garofalo Health Care and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $518M | XXX | $518M | XXX | XXX | XXX |
| EV (current) | $758M | XXX | $758M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 8.5x | XXX | 9.7x | XXX | XXX | XXX |
| EV/EBIT | 14.5x | XXX | 12.3x | XXX | XXX | XXX |
| EV/Gross Profit | 1.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 19.3x | XXX | 21.2x | XXX | XXX | XXX |
| EV/FCF | 27.6x | XXX | 50.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGarofalo Health Care's last 12 month revenue growth is 2%
Garofalo Health Care's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Garofalo Health Care's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Garofalo Health Care's rule of X is 22% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Garofalo Health Care and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | 19% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 22% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 73% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Garofalo Health Care acquired XXX companies to date.
Last acquisition by Garofalo Health Care was XXXXXXXX, XXXXX XXXXX XXXXXX . Garofalo Health Care acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Garofalo Health Care founded? | Garofalo Health Care was founded in 2000. |
| Where is Garofalo Health Care headquartered? | Garofalo Health Care is headquartered in Italy. |
| How many employees does Garofalo Health Care have? | As of today, Garofalo Health Care has 2.7K+ employees. |
| Who is the CEO of Garofalo Health Care? | Garofalo Health Care's CEO is Ms. Maria Laura Garofalo. |
| Is Garofalo Health Care publicy listed? | Yes, Garofalo Health Care is a public company listed on MIL. |
| What is the stock symbol of Garofalo Health Care? | Garofalo Health Care trades under GHC ticker. |
| When did Garofalo Health Care go public? | Garofalo Health Care went public in 2018. |
| Who are competitors of Garofalo Health Care? | Similar companies to Garofalo Health Care include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Garofalo Health Care? | Garofalo Health Care's current market cap is $518M |
| What is the current revenue of Garofalo Health Care? | Garofalo Health Care's last 12 months revenue is $534M. |
| What is the current revenue growth of Garofalo Health Care? | Garofalo Health Care revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Garofalo Health Care? | Current revenue multiple of Garofalo Health Care is 1.4x. |
| Is Garofalo Health Care profitable? | Yes, Garofalo Health Care is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Garofalo Health Care? | Garofalo Health Care's last 12 months EBITDA is $89.4M. |
| What is Garofalo Health Care's EBITDA margin? | Garofalo Health Care's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Garofalo Health Care? | Current EBITDA multiple of Garofalo Health Care is 8.5x. |
| What is the current FCF of Garofalo Health Care? | Garofalo Health Care's last 12 months FCF is $27.5M. |
| What is Garofalo Health Care's FCF margin? | Garofalo Health Care's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Garofalo Health Care? | Current FCF multiple of Garofalo Health Care is 27.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
